<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02367313</url>
  </required_header>
  <id_info>
    <org_study_id>BTA798-203</org_study_id>
    <secondary_id>2014-001785-95</secondary_id>
    <nct_id>NCT02367313</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study of Vapendavir in Asthmatic Adults With Symptomatic Human Rhinovirus Infection</brief_title>
  <acronym>SPIRITUS</acronym>
  <official_title>A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Dose-ranging Study of Vapendavir in Moderate to Severe Asthmatic Adults With Symptomatic Human Rhinovirus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biota Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vaxart</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 2 protocol is designed to compare two dose levels of Vapendavir versus placebo.
      The objectives are to obtain safety and efficacy data in moderate to severe asthmatic
      patients, aged 18 to 75 years at risk of loss of asthma control due to presumptive Human
      Rhinovirus infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter trial to be conducted at approximately 60 sites among 6−8 northern
      hemisphere countries in North America and Central Europe. Sufficient patients will be
      randomized in order to recruit 150 subjects who are laboratory confirmed for human rhinovirus
      (HRV) infection. Depending on HRV PCR positivity rates, it is expected that randomization of
      250-480 subjects will be required to achieve this number of subjects with HRV infection.

      Appropriate asthma subjects will be screened up to 180 days prior to presentation at the
      study site with symptoms of presumed HRV infection for potential study inclusion on Study Day
      1. The study drug treatment period has a duration of 7 days, beginning on Study Day 1.
      Follow-up study visits to the clinic occur on Study Days 3, 5, 7, 14, 21, and 28 with a
      telephonic final safety follow-up visit conducted on Study Day 35. Thus, depending on the
      duration of the screening period, a subject's duration of participation can be estimated to
      last from approximately 37 days up to 215 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Asthma Control Questionnaire-6 (ACQ-6)</measure>
    <time_frame>Baseline (Day 1) to Study Day 14</time_frame>
    <description>Least Square (LS) mean change from baseline (Day 1) to Study Day 14 in ACQ-6 total score</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">455</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vapendavir 264 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vapendavir 264 mg and matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vapendavir 528 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vapendavir 528 mg and matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vapendavir</intervention_name>
    <description>Vapendavir 264 mg twice daily</description>
    <arm_group_label>Vapendavir 264 mg</arm_group_label>
    <other_name>BTA798</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vapendavir</intervention_name>
    <description>Vapendavir 528 mg twice daily</description>
    <arm_group_label>Vapendavir 528 mg</arm_group_label>
    <other_name>BTA798</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Moderate and severe male and female asthma subjects aged 18 to 75 years, (inclusive)

          2. Established clinical history of Asthma for at least 1 year, and a history within the
             last 14 months (prior to screening) of asthma exacerbation due to presumed viral
             respiratory infections, which required asthma rescue medication treatment.

          3. The asthma subjects will be currently taking at least medium-dose or high-dose ICS
             defined as fluticasone at a dosage of at least &gt;264 µg daily and may be taking other
             asthma medication preparations. The asthma subjects' medication regimen must be stable
             for at least 4 weeks before screening.

          4. Subjects will have at screening or within the last year, documented variable airway
             obstruction as indicated by an increase in FEV1 (&gt;12%) to short acting bronchodilator,
             or positive methacholine challenge, or positive histamine challenge (PC20 &lt;8 mg/mL).

          5. Upon presentation to the clinic with cold symptoms, subjects will be required to be
             randomized and treated within 48 hours of symptom onset and will be qualified for
             presumptive rhinovirus infection by:

               1. clinical exam and the presence of each of the following Day 1 WURSS-21 symptoms
                  at a severity of 2 or greater: runny nose, sore throat, scratchy throat.

               2. subjects must also have a minimum total symptom score on the Day 1 WURSS-21 of 20
                  points.

               3. subjects will be further qualified as presumptively infected with HRV via
                  exclusion of subjects having significant fever and exclusion of subjects testing
                  positive for influenza via Rapid Antigen Test.

        Exclusion Criteria:

          1. Subjects presenting to the clinic with a current severe asthma exacerbation will be
             excluded from randomization, as well as any subject with an additional underlying
             respiratory medical condition other than asthma such as COPD, cystic fibrosis, or
             chronic sinusitis, or any other uncontrolled clinically significant disease which
             would interfere with the assessment outcomes or subject safety.

          2. Female subjects must not be pregnant or breastfeeding. Females of childbearing
             potential must be willing to utilize a double barrier method of contraception, as
             defined in this protocol, regardless of any hormonal contraception they may be
             concomitantly receiving.

          3. Male subjects must agree to use a method of birth control defined in this protocol.

          4. The use of medications known to moderately or severely inhibit or induce cytochrome
             (CYP) 3A4 and 2C19 enzymes, or those known to be sensitive substrates (with a narrow
             therapeutic range) of these CYPs are restricted.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Novotney-Barry</last_name>
    <role>Study Director</role>
    <affiliation>Biota Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Flagstaff</city>
        <state>Arizona</state>
        <zip>86001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational Site</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <zip>95207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Oviedo</city>
        <state>Florida</state>
        <zip>32765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigation site</name>
      <address>
        <city>Palmetto Bay</city>
        <state>Florida</state>
        <zip>33157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Twin Falls</city>
        <state>Idaho</state>
        <zip>83301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <zip>68123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota investigational site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Ocean</city>
        <state>New Jersey</state>
        <zip>07712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <zip>11570</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Middleburg</city>
        <state>Ohio</state>
        <zip>44310</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigation site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Greenfield</city>
        <state>Wisconsin</state>
        <zip>53228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Sofia</city>
        <zip>1202</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Sofia</city>
        <zip>1618</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Stara Zagora</city>
        <zip>6000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Jindrichuv Hradec</city>
        <zip>37701</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Kyjov</city>
        <zip>69733</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Lovosice</city>
        <zip>41002</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Melnik</city>
        <zip>27601</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Prague</city>
        <zip>18200</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Rokycany</city>
        <zip>33722</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Tbilisi</city>
        <zip>0102</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Tbilisi</city>
        <zip>0186</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-044</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Kielce</city>
        <zip>25-734</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Krakow</city>
        <zip>31-023</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Lodz</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Lublin</city>
        <zip>20-552</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Skierniewice</city>
        <zip>96-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Warsaw</city>
        <zip>01-868</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-044</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Wroclaw</city>
        <zip>51-162</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Brasov</city>
        <zip>500112</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Bucharest</city>
        <zip>020671</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Craiova</city>
        <zip>200446</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Mures</city>
        <zip>547530</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biota Investigational site</name>
      <address>
        <city>Sibiu</city>
        <zip>550360</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Czech Republic</country>
    <country>Georgia</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2015</study_first_submitted>
  <study_first_submitted_qc>February 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2015</study_first_posted>
  <disposition_first_submitted>March 17, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>March 17, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 20, 2017</disposition_first_posted>
  <last_update_submitted>March 17, 2017</last_update_submitted>
  <last_update_submitted_qc>March 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Symptomatic Human Rhinovirus Infection</keyword>
  <keyword>Moderate to Severe Asthma</keyword>
  <keyword>Antiviral</keyword>
  <keyword>Cold</keyword>
  <keyword>Aviragen Therapeutics, Inc.</keyword>
  <keyword>Aviragen Therapeutics</keyword>
  <keyword>Aviragen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

